<div id="readability-page-1"><p>In a report released today, Joseph Catanzaro from Mizuho Securities reiterated a Buy rating on Nurix Therapeutics, with a price target of <span id="expert-recommendation-target">$30.00</span>.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>According to TipRanks, Catanzaro is a 4-star analyst with an average return of <span>8.5%</span> and a 43.26% success rate. Catanzaro covers the Healthcare sector, focusing on stocks such as Apogee Therapeutics, Celldex, and Revolution Medicines.</p> <p>In addition to Mizuho Securities, Nurix Therapeutics also received a Buy from H.C. Wainwright’s Robert Burns in a report issued today. However, yesterday, Morgan Stanley maintained a Hold rating on Nurix Therapeutics (NASDAQ: NRIX).</p></div>

NRIX

<p>Mizuho Securities' Joseph Catanzaro reaffirmed a Buy rating for Nurix Therapeutics with a $30 price target. Catanzaro, a 4-star analyst, has an average return of 8.5% and a 43.26% success rate. Nurix also received a Buy rating from H.C. Wainwright, while Morgan Stanley maintained a Hold rating.</p>

Mizuho Securities Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)